patentstorm.us

Therapeutic agent for rheumatoid arthritis

Patent Number: 8440893
Publication Date: 2013-05-14
Inventor:

When C60 was added to synovial fibroblasts, infiltrating lymphocytes, and macrophages, and the inflammatory cytokine production level was measured, the inflammatory cytokine production level was significantly suppressed in all cells. Furthermore, when C60 was added to osteoclast precursor cells and cultured in the presence of osteoclast differentiation-inducing factors, a certain concentration or more of C60 suppressed their differentiation into osteoclasts. Observation of the effect of C60 ...

Nanowire-based membrane electrode assemblies for fuel cells

Patent Number: 8440369
Publication Date: 2013-05-14
Inventors: ; ;

The present invention discloses nanowires for use in a fuel cell comprising a metal catalyst deposited on a surface of the nanowires. A membrane electrode assembly for a fuel cell is disclosed which generally comprises a proton exchange membrane, an anode electrode, and a cathode electrode, wherein at least one or more of the anode electrode and cathode electrode comprise an interconnected network of the catalyst supported nanowires. Methods are also disclosed for preparing a membrane ...

Scanning probe microscope

Patent Number: 8438661
Publication Date: 2013-05-07
Inventors: ; ; ;

The invention relates to a scanning probe microscope comprising: a specimen holder holding a specimen; and a probe for scanning the relief of the upper surface of the specimen, which probe is movable in a vertical direction and two orthogonal horizontal directions, wherein the upper surface of the specimen is tilted relative to at least one of the two orthogonal horizontal ...

Liposomal formulations of anthracycline agents and cytidine analogs

Patent Number: 8431806
Publication Date: 2013-04-30
Inventors: ;

Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug ...